Alrizomadlin,Pembrolizumab
ascentage pharmaceuticals,merck
['ascent', 'alrizomadlin', 'melanoma', 'pembro', 'ascentage']
live from asco 2023 | for the third consecutive year, ascentage pharma releases promising results of alrizomadlin plus pembrolizumab in patients with cutaneous melanoma that failed immuno-oncologic (io) therapies #prnewswire #prnewswire 
Stock Market News and Press Releases. #StockMarket & #Crypto